Search Immortality Topics:

Page 112«..1020..111112113114..120130..»


Category Archives: BioEngineering

Scientists Create Proteins That Don’t Crosstalk with Other Molecules – Interesting Engineering

Cells in our bodies communicate important messages via interactions between proteins. In order for these messages to be clearly and accurately conveyed, every protein needs to talk to only one other partner, cutting out any crosstalk with other similar proteins.

A new MIT study has unveiled how crosstalk between these proteins can be avoided by using cells. Furthermore, the study has also shown how there are many more potential protein interactions that cells have yet to use.

This could assist synthetic biologists in creating new pairs of proteins to act as artificial circuits which would be useful when diagnosing diseases.

RELATED: INCREDIBLE ARTIFICIAL PROTEIN OPENS UP POTENTIAL FOR SMART CELL THERAPIES

The MIT researchers created new pairs of signaling proteins to show how these can be useful in linking new signals to new outputs by engineering E. coli cells.

"Using our high-throughput approach, you can generate many orthogonal versions of a particular interaction, allowing you to see how many different insulated versions of that protein complex can be built," said Conor McClune, an MIT graduate student and the lead author of the study.

In their study, the researchers used a two-component signaling pathway that is found in bacteria. These pathways have evolved through a process that allows cells to duplicate genes to signal proteins they already have. Then they mutate them and end up creating similar protein groupings.

Its intrinsically advantageous for organisms to be able to expand this small number of signaling families quite dramatically, but it runs the risk that youre going to have crosstalk between these systems that are all very similar," said Michael Laub, MIT professor of Biology and senior author of the study.

Laub continued, "It then becomes an interesting challenge for cells: How do you maintain the fidelity of information flow, and how do you couple specific inputs to specific outputs?"

Finally, Laub said, "What we found is that its pretty easy to find combinations that will work, where two proteins interact to transduce a signal, and they dont talk to anything else inside the cell."

What the study also assists with is a new strategy for creating synthetic circuits. One of the applications could be designing circuits that notice the presence of other microbes. These circuits could prove useful when creating probiotic bacteria, which helps diagnose infectious diseases.

"Bacteria can be engineered to sense and respond to their environment, with widespread applications such as smart gut bacteria that could diagnose and treat inflammation, diabetes, or cancer, or soil microbes that maintain proper nitrogen levels and eliminatethe need for fertilizer," said Jeffrey Tabor, an associate professor of bioengineering and biosciences at Rice University.

Tabor continued, "To build such bacteria, synthetic biologists require genetically encoded 'sensors.'"

Furthermore, if adapted for use in human cells, the new study's approach could also assist biologists in designing novel ways to create human T cells, which destroy cancer cells.

The study was published on Wednesday in Nature.

Go here to read the rest:
Scientists Create Proteins That Don't Crosstalk with Other Molecules - Interesting Engineering

Posted in BioEngineering | Comments Off on Scientists Create Proteins That Don’t Crosstalk with Other Molecules – Interesting Engineering

Ottawa-based treatment an unprecedented leap forward in addressing damage after heart attack – Ottawa Citizen

Veronika Sedlakova, post-doctoral fellow (L), Sarah Mclaughlin, PhD(c), and Dr. Emilio Alarcon, principal investigator and laboratory director, University of Ottawa Heart Institute, have developed a recombinant human collagen matrix for cardiac tissue repair. October 24, 2019. Errol McGihon / Postmedia

It took years for Emilio Alarcon and his University of Ottawa Heart Institute research team to fully believe what they were seeing that a gel they had developed containing human collagen was repairing damaged hearts in mice.

They repeated their research study several times, coming up with randomized, blinded results, just to make sure the findings were correct.

We had to complete it many times because we couldnt believe it, he said.

The results of that work, five years in the making, were published in the prestigious journal Nature Communications on Friday. Alarcon and Erik Suuronen, a scientist in the division of cardiac surgery and director of its biomaterials and regeneration program, are lead authors.

The injectable material is the first in the world prepared using human collagen and is being called an unprecedented leap forward in addressing repair of cardiac muscle after a heart attack.

The work is still years away from clinical use on humans, but the findings are expected to attract attention because of the potential of the gel, which is designed to be injected into the hearts of patients with damaged heart tissue after a heart attack.

Alarcon said his team believes it performs better than any of the cell-based therapies or drug treatments currently available. The treatment works, he said, by increasing the number of cardiac muscle cells and blood capillaries in the tissue around damaged areas of the heart. The gel also helps bring more wound-healing cells to the site to promote repair.

Heart diseases are the leading cause of death around the world, and coronary artery disease, which can lead to a heart attack, is the most common.

About 10 per cent of people who have a heart attack (or myocardial infarction) will develop scarring and thickening of the heart wall that can lead to heart failure, which has a high mortality rate and its treatment is costly to the health system.

Alarcon noted that patients in remote areas without easy access to health care and those who dont seek immediate treatment or dont know they had a heart attack are more likely to suffer heart muscle damage. The treatment being developed by the heart institute team restored heart function in mice with scarred cardiac muscle.

The heart institutes BioEngineering and Therapeutic Solutions (BEaTS) team are hopeful their human collagen gel will one day lead to a recovery of heart function and prevent heart failure in humans, said Alarcon, but more testing is required.

The study published Friday is a first step toward that potential treatment, he said.

In Canada, approximately 600,000 patients live with advanced heart failure and health-care costs amount to more than $2.8 billion every year. As people live longer, both the number of patients and the cost of treatments are likely to increase.

ALSO IN THE NEWS

Mistake airline fares are the best way to score super cheap plane tickets. Heres how

Canadian scientists say they have produced the rarest drug on earth for cancer treatment

Fourth federal government office building treated for bedbugs

See the original post:
Ottawa-based treatment an unprecedented leap forward in addressing damage after heart attack - Ottawa Citizen

Posted in BioEngineering | Comments Off on Ottawa-based treatment an unprecedented leap forward in addressing damage after heart attack – Ottawa Citizen

Plastic: The many good uses of a vilified modern material – The Irish Times

Plastic: Cant Live With It, Cant Live Without It is a new exhibition at Dublins Science Gallery. It draws our attention to our complex relationship with this ubiquitous material. While a lot of focus of late has been on the environmental damage of single-use plastics particularly on bird and fish life the reality is that plastic is also used in a myriad of positive ways in industry and medicine.

Plastic is so vilified now, but people underestimate the reliance we have on it for healthcare. Modern healthcare would be impossible without the many plastic-based medical products we take for granted, such as pills coated with plastic to control the release of the drug once ingested, says Prof Michael Monaghan, assistant professor of biomedical engineering at Trinity College Dublin.

Prof Monaghan, curatorial adviser to the Science Gallery exhibition, has helped create an exhibit on open-source plastic medical devices developed through 3D printing. He believes plastic is superior to many other materials, because its cheap and because each piece can be sterilised.

Students in the masters in bioengineering at Trinity design devices that are needed in healthcare (eg a diagnostic tool for malaria, or a box for the safe disposal of needles), and we upload their codes to our website so that anyone around the world can download them. 3D printing in a smart connected world allows us to 3D print anything we want in plastic, he explains.

The biohybrid robotic respiratory simulator is another exhibit made from flexible plastic and electrics. It, too, highlights the role of plastic in healthcare. Markus Horvath from Massachusetts Institute of Technology says this particular model is used for teaching students as well as for inventing new medical devices.

The impact of plastics in a destructive way is well documented but they are also used in medical technology to save lives, says Horvath. Another exhibit is of 3D-printed plastic human organs, used by students to practise surgery.

Several exhibits, however, focus on the overconsumption of plastic. One asks whether people would wear a self-tracking device that would capture their consumption of plastic and shame them or celebrate their results. Another has playfully constructed an environmental checkpoint to protect natural resources that people with plastics (even fleece jackets, chewing gum, and pens) would not be able to pass.

And an exhibit entitled The Peoples Plastic is a shelving unit filled with plastic bottles with warning labels highlighting the damage single-use plastics do to the environment. Mindy OBrien from the environmental NGO Voice says: Its a great idea, but I think such labels should also have information on the plastics used in packaging, because some chemicals leach into food.

OBrien, who works on initiatives to reduce plastic pollution, remains concerned about where much of single-use plastic ends up. I think deposit-refund schemes are a good way of collecting plastic bottles for recycling but Id really like to see deposit-refund schemes for reuse of plastic bottles. Ultimately, we need a paradigm shift where we look at the product (eg vending machines for water) rather than the packaging.

A ban on single-use plastic items including cotton buds, polystyrene cups, plastic cutlery and straws is due to be imposed from 2021. Other EU legislation will require 50 per cent of plastic waste to be recycled by 2025 and all plastic to be easily recyclable by 2030. With these changes in mind, eco-designers are turning their attention to alternatives to petrochemical-based plastics and new uses for recycled plastic.

An exhibit entitled An B Bheannaithe (The Blessed Cow) shows how a byproduct of whey protein production can be used to create a compostable bioplastic. Visitors to the exhibition can also try making this bioplastic at workshops.

A tricycle made from prefabricated sheets of recycled plastic shows a potential new use for what might be a glut of recyclable plastics if and when the EU Single-Use Plastics Directive is enforced. An original 1968 Italian-designed Monobloc chair is also on show as an example of an easy-to-make, durable, low-cost stackable chair made from recycled plastic.

Abigail Murphy fromthe Environmental Protection Agency hopes the exhibition will raise awareness of plastic as an innovative material and not just something that is overconsumed. Plastics are priority areas for [our waste prevention office], and we offer innovation grants for the circular economy [where materials are brought back into circulation rather than disposed of].

Ruth Doyle, another curatorial adviser, who has a PhD in sustainable lifestyles and runs @missionzerowaste on Instagram, hopes the exhibition will promote conversations about overconsumption in general of which the plastics problem is a symptom.

There is a need for more ethical and conscious consumption, and this can be a gateway to awareness of other environmental issues. There are substitutes for a lot of plastic items some of which are smart, modern alternatives such as reusable nappies. The problem is they are still niche products, so they need to be more readily available, says Doyle.

And has the Science Gallery changed any of its own practices? We used a sustainable events company when mounting the exhibition, which will tour to five locations around Ireland. This company planned the reuse of materials 30 per cent of which is plastic for schools, festivals and community centres once the exhibition is over, explains Aisling Murray, exhibitions manager at the Science Gallery.

The gallery has also recently added a composting bin alongside its general waste and recyclables bins, so that customers can dispose of compostable cups correctly. Next week, a hydration station will be installed. The Science Gallery cafe has also switched from plastic bottles to cans for all drinks sold on site.

Plastic: Cant Live With It, Cant Live Without It will run in the Dublin Science Gallery until February 9th, 2020, after which it will tour to Drogheda, Letterkenny, Wexford, Limerick and Galway. dublin.sciencegallery.com/plastic

Read the original:
Plastic: The many good uses of a vilified modern material - The Irish Times

Posted in BioEngineering | Comments Off on Plastic: The many good uses of a vilified modern material – The Irish Times

Edited Transcript of XVIVO.ST earnings conference call or presentation 24-Oct-19 12:00pm GMT – Yahoo Finance

GOTEBORG Oct 25, 2019 (Thomson StreetEvents) -- Edited Transcript of Xvivo Perfusion AB earnings conference call or presentation Thursday, October 24, 2019 at 12:00:00pm GMT

Ladies and gentlemen, welcome to the XVIVO Perfusion Third Quarter 2019 Report Webcast. Today, I am pleased to present Magnus Nilsson, CEO; and Christoffer Rosenblad, CFO.

I will now hand you over to Magnus Nilsson. Sir, please go ahead.

Thank you, and welcome to the 28th quarterly report of an independent XVIVO Perfusion. And this is, as we said, the interim report for the third quarter.

Next slide, please. So the highlights. It's been an important quarter for us, and I'll try to put you into the picture.

Q3, first time, rolling 12 months nondurable sales over SEK 200 million. We have received a patent approval for the Perfadex Plus, and we have started a very interesting collaboration to develop fast diagnostic tests using biomarkers at -- to be used in EVLP and similar.

And repeating for the full year, the most important highlights is, of course, the PMA for XPS and STEEN Solution, the patents for the heart preservation fluids. The positive results of the clinical safety studies in Lund on the heart device and the deepening -- deepened collaboration or cooperation with Lung Bioengineering.

So next slide, please. So the sales highlights for the quarter was that we sold the second XPS to China, which is really interesting market. I'll come back to that. We -- also Lung Bioengineering has acquired their second XPS when they opened their new EVLP center, and we have a continued stable gross margin during growth for the quarter and for the year. We can see for the year continued strong sales all over the year, nondurable goods, 25% in Q3. Warm nondurable growth rolling -- is rolling on a 40% level year-to-year. And we see also continuation of the positive sales trend for cold preservation, which is an indication that the global market for transplantation is growing also outside that main markets.

Next slide, please. So some more numbers here. The profit and loss statement to be highlighted is, of course, the net sales, but then the -- again, the stable gross margin of nondurable goods. That's the important gross margin, of course. And we are running on a level pretty similar level on the selling expenses. We built up continuously our sales force, which is more of a customer support. That is technical advisers being out on the clinics, helping them to perform EVLP.

We can also see that we are a little bit higher R&D. Same thing here. We developed our clinical teams since we are in a situation where we start up a number of clinical studies. And then that we're still doing all this intensive investment in R&D and built up our organization still can keep a very good profit level -- counted on the EBITDA level. There is one item affecting comparison. And that is, of course, as I said before, that we have mirrored bonus program for the employees outside Sweden, which is based on the share price, mirroring the Swedish warrant program.

Next slide, please. So we are in an intensive phase of the company, where we strengthen ourselves in hiring new competencies and capacities, such as our first transplant surgeons and other clinical trial experts. So the buildup of the heart and PrimECC teams that will run the multicenter studies over the world, and we're also extending the team supporting the Lung EVLP market development.

Next slide, please. So a few words about the Chinese transplant market. It is a very fast-growing market, a lot of activities. I think more than 10 new centers have been certified to do transplants in China. It's growing from relatively low level But with a very high speed, and it has been about a 50% increase during the last years and we -- something like that probably this year as well. So therefore, it's very encouraging that we now have placed our second or sold our second EVLP in China to the second largest transplant clinic in China, the -- one of the major hospitals in Beijing. And this clinic makes about 100 -- over 100 transplant last year. And you can -- necessity they are increasing very rapidly, and they're just being trained actually these days. We -- just yesterday, I got a report that the training was -- the first training practice run was performed in Beijing. So this continues to be one of the more exciting markets where we focus on, and we'll focus on in the future.

Then another thing, the important product for us, obviously, is Perfadex. And as you know, we have a upgraded ready-to-use product that -- so that -- which is more convenient and safe for the patients. You don't have to mix at site. It's now been patented in Europe, which is very encouraging. And we have submitted patent applications in all important markets.

Next slide, please, #8. XVIVO and MyCartis collaboration. MyCartis is a company specialized in developing fast analysis tools and assays, so we will -- we are now part in a collaboration, where we will -- they will help us on developing these assays, which can be used and generate results within 20 minutes at bedside, so to speak, on the EVLP, which is thought to be very important in assessing and identifying how good lungs and other organs are after XVIVO perfusion. So these biomarkers and this fast evaluation of biomarkers has a potential to increase the number of EVLP and also increase the, obviously, the chances of positive outcomes for the patients.

Next slide. We continue to cooperate with Lung Bioengineering, as I said. And they -- and not only with Bioengineering. Actually with another entities in United Therapeutics. So they have opened now their second EVLP center in Jacksonville, Florida, in addition to their center in Maryland. And we collaborate both -- we're helping them to set up using the XPS EVLP process and also are cooperating in marketing of these services on centers so that the centers can choose to either use EVLP, if they have an EVLP system themselves; or if they want to use these services, which uses our products, but at the United therapeutics or Lung Bioengineering sites. We also have started collaborating with them in their research on the xenotransplantation.

Next slide, please. So this part is about the R&D pipeline, which we drive with high speed and a lot of focus to ensure future growth and to employ the technology and the experience we've had drawn on lungs into other organs.

So the investment in future EVP (sic) [EVLP] growth. So this is about developing the EVLP or the lung indication to use it more in order to get more organs available to the patients. So we developed the XPS technology with new sensors, and we also then again want to develop markers to use -- to be used in conjunction with the running of the XPS.

We're also looking at the clinical development, in expanded use of donation after circulatory death. That is the usual DCD lungs. And also for anti-infection therapy, we can -- we see now one of the results of that support is the recent publication on virus risk hepatitis C reduction during EVLP. And we also developed further the EVLP protocol for the ventilation strategy; organ proning, which is to turning it to get perfusion on all sides, et cetera. So a lot of development going on in order to make the EVLP even better in determining which organs that can be used. We also investigate the immunological response to EVLP, targeting both short-term organ function and long-term survival.

Next slide. So if you look at employing this technology on new organs. We have, of course, our #1 priority, the heart transplant project, which is about optimizing preservation to prolong the time outside the body, because we know that a heart is very demanding in the sense it can only survive 4 to 5 hours outside the body today. And we have the aim to keep the organ in better shape during the process and, therefore, both being able to use older donors and also to extend the time outside the body to be able to use organs from further away than today.

The #2 priority is the PrimECC. It's about an optimized solution. So it's based on our knowledge and technology around Perfadex and STEEN Solution to have an optimized priming solution to reduce the known side effects.

And as a third priority and a lower priority, but still very interesting is to see how we can employ the STEEN Solution technology on the liver and kidney transplants. We have been supporting that for a time coming -- for a time where in clinical studies, STEEN Solution with some additives has been used, both in liver and in kidneys today clinically. The fourth priority, which is a relatively low priority, but may be interesting in the longer-term future is perfusion of the isolated organs and tissues.

Next slide, please. So again the heart transplantation. It's a heart perfusion and preservation solution and device developed by Professor Steen originally. And that first device prototype has been used in a number of preclinical trials, where he's shown -- showed that this non-oxygenated time, called NIHP, results in a better organ quality. So the idea is to keep the organ resting, but profused with this new solution in a low temperature, reducing the metabolism, which then facilitates a longer preservation time. And it's shown up to 24 hours in pigs in publications and even longer.

It's also being used in xenotransplantation from pig to monkey. And using that device, they were able to increase the survival up to 6 months. This was never been done before. That was published in Nature in December of last year. And after that, the technology has been employed in Lund University Hospital in a safety clinical trial. The first 6 patients were evaluated after 6 months and partly public -- publicized, where they can said that the heart can be safely preserved with this NIHP technology, resulting in successful transplantations and the reduced risk of ischemic induced reperfusion injury. More patients have been included with this, and the study is ongoing in parallel to all other activities.

Next slide please, 14. So we've been working very hard now with a number of activities, especially the clinical team build up, ramp-up of machine, disposable and solution production. And we see a huge interest in worldwide and the clinical participation in the clinical trials, both in Europe, U.S. and Australia. And on preparations for all these 3 are ongoing and Europe, obviously, first. We have several authorities that have cleared this, but we will -- we're looking to have all centers -- all regulatory authorities, all centers clearing the protocol before we start the inclusion. This moves on very well. And of course, the important is not the first patient in. The important is the last patient out, so that means that we need to have all the centers up and running. That's the most important, and that's what we're focusing on.

Next slide, please. PrimECC. So PrimECC background, just for those who have not heard it. Priming solutions are used in all runs of heart-lung machines, and they're primed before they can -- you start using them in the patient. And that means that about 1.5 liter of blood of the patient comes into the circuit of the heart-lung machine and that 1.5 liter of priming solution goes into the patient. That has -- of the solution used today, there is a number of known side effects of the solutions used today. About 600,000 to 700,000 of these operations are done worldwide each year. And the whole idea now is that the PrimECC has been developed to alleviate these side effects. That's the whole idea of this project. And we have done quite a bit so far.

And next slide please, 16. So it's a patent in all major markets, it's CE marked. We have done a clinical study of 40 plus 40 patients, which show that PrimECC is safe to use. It also show that we can improve fluid balance, reduction of side effects using the heart-lung machines primed with PrimECC.

So what we do right now is to scale up both the production. We had to change the bag for regulatory reasons to eco-friendly bag, and we've done all that validation of production. We have submitted that -- all that technical file to the notified body, which are looking at the file. And as soon as they are done, we can then start up the clinical trial. We have meanwhile also built up the clinical and regulatory team around the product, PrimECC product, which will run than the clinical trial and the regulatory implications.

So the whole idea here is to make a few, 1 or 2 studies, to get more clinical documentation showing then and developing the effects of this in reducing the side effects. It's a high interest from the clinics to participate in these studies.

Next slide, please. So we look forward. We continue to focus on the thoracic transplantation. That's primary focus. It's lungs, obviously, further to support the EVLP technology and clinical practice of using it; the heart preparation for multicenter studies in all major markets, that's U.S., Europe and Australia; and also -- and PrimECC preparation for the multicenter study, waiting for the regulatory authorities' go ahead.

We are looking at the abdominal transplantation, a new indication. It's a secondary focus, but we feel it's very interesting to see how we can use the technology and the experience further into organs in abdominal organs like liver and kidney. And we have been supporting with good results the clinical trials using STEEN Solution in these organs, and we further investigate how to employ the technology further and see how we can create value of what we've done in lungs and the hearts to this important and interesting indications.

So the long-term goals: Solidify the position in thoracic surgery. And then build new business using the STEEN Solution technology in liver and kidney. That's long term goal.

And we are open for questions, please.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from the line of Daniel Albin from Danske Bank.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [2]

--------------------------------------------------------------------------------

Can you hear me, guys?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [3]

--------------------------------------------------------------------------------

Yes.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [4]

--------------------------------------------------------------------------------

Yes. Good. Okay. So I have a couple of questions. My first question is maybe a bit more of a technicality, but looking at the sales of cold preservation, this quarter seems to be a pretty good one. I'm just wondering if you could elaborate a bit more on the reasons behind this strength. And how we should view the growth rates going forward? You're mentioning that the global market is growing. Is it growing more than the 6% last few years? Or how should we view this?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [5]

--------------------------------------------------------------------------------

I think it's mirroring a worldwide growth of lung transplantation as such. I don't think we should pay too much attention to a single quarter. We will see in the long-term trend if that will continue. We know that more -- we're seeing more countries buy and clinics buying also in South America and so forth, but we don't really know if that will increase over the kind of long-term trend of 6% to 7%. It's too early to say.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [6]

--------------------------------------------------------------------------------

Okay, yes. And my second question then. So you're mentioning China here growing very fast, and I'm wondering if you could give us maybe some bit more clarity on the regulatory pathway required by the FDA or the MPA nowadays regarding your products and then Perfadex and also the EVLP solution. What are the lead times that required clinical studies you're obligated to do, et cetera?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [7]

--------------------------------------------------------------------------------

So normally, it's -- traditionally or historically, it takes about 2 years to get product registered in China if you have the right documentation. We already STEEN Solution. We have several of the disposables already approved in China. We have -- the things missing so far is the XPS. However, it's okay to use the XPS in -- as an exception still in -- since transplantation -- lung transplantation is very young there, they allow them to use them anyways.

But we are in the -- rather late -- should be in the rather late stage of having XPS approved. And obviously hard to say, but we -- I would imagine that within -- in the next 6 to 9 months, we should have a registration of XPS in China. We have Perfadex as before registered.

--------------------------------------------------------------------------------

Daniel Albin, Danske Bank Markets Equity Research - Research Analyst [8]

--------------------------------------------------------------------------------

Okay. And how do you view then the, I guess, the ramp-up of EVLP procedures in China?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [9]

--------------------------------------------------------------------------------

It's obviously early stage. But again, we see how quickly it grows. What they have problems with in China is that they are not used to good ways of taking care of the donor. So the donor management is rather, let me say, not too developed, which means that the lungs or the organs they receive vary in quality quite a bit, and that's what they have -- they said that to us that for that reason, they think EVLP is very important for them in order to check if the organs are okay since again, the variation, I should say, of the organ quality is pretty large. So they believe that EVLP will be an important addition to their clinical practice, although we have to say that this is, again, transplantation -- lung transplantation is very new, and obviously, this technology is for them, totally new.

On the other hand, I have experienced from other product -- taking out the products to China, and they always want to start with the most advanced. They never go for the simple solution. So from my time in Vitrolife, I know that once the Chinese start up, they want to go for the cutting-edge technology, and I think that's why they have been so interested in taking on this EVLP. But we will probably have to wait a little bit longer probably -- maybe a year or so until we see a significant increase in EVLPs there. But I have no doubt that China will be a very important market for us just in the next 2 to 3 years.

--------------------------------------------------------------------------------

Operator [10]

--------------------------------------------------------------------------------

(Operator Instructions) Our next question comes from the line of Arvid Necander from Redeye.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [11]

--------------------------------------------------------------------------------

Okay. So my first question relates to the collaboration with United Therapeutics. So when we saw the delivery of the first machine, we saw quite a big uptick in the sales growth related to warm perfusion. How correlated was this? And do you expect to see a similar impact now that the second machine is delivered?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [12]

--------------------------------------------------------------------------------

Yes. It's a tough question because I try to predict what other people do, but we know that they're very dedicated in providing this service to the U.S. clinics. They are very dedicated. They put a lot of money into having the service in order to have more transplant available. I know their CEO is very -- is very dedicated in advancing this technology in order to get more patients, transplantation -- transplanted.

So I can only judge from what I see in terms of how many -- how much resources they put in. And what kind of big focus they have. So I'm convinced that over the years, they will increase significantly the number of -- or percentage of EVLPs done by their service compared to the overall number. And for us, it's very good because I think that a lot of clinics are not big enough to -- can employ this technology by themselves, and that I foresee more or less that in the next year or so, we will see a pretty rapid increase in this service. I would be surprised otherwise.

We have already been starting co-marketing with them, helping or going traveling with them to clinics and to explain the difference and the similarities for the clinics using this service versus using our technology. So I can just say that they're very determined and put a lot of resources into it, which I think is very encouraging.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [13]

--------------------------------------------------------------------------------

Okay. And also, if you could just address the recruitments you've made a bit more. How do you see the headcount increasing going forward? Are we -- should we expect to see the same trend? Or do you see a bit of a slowdown now going forward?

--------------------------------------------------------------------------------

Magnus Nilsson, Xvivo Perfusion AB (publ) - CEO & MD [14]

--------------------------------------------------------------------------------

Yes. So what we've done -- we can say that we have kind of a pretty steady growth when it comes to marketing. It's no explosion there. It's an add-on every now and then when we -- in more or less parallel with the sales increase. What we've done is to built our development team. So to run these huge clinical trials for us, several -- I mean, heart will be on all continents. We had to build more competence and teams in the heart transplantation field and also, to some extent, on the PrimECC thing.

So this will continue for some quarters more to complete the buildup of those clinical teams. After that, I foresee that we go back to a more gradual increase again. So maybe a couple of quarters where we complete the kind of recruitment of these clinical teams. After that, I see more -- going back to a more gradual growth in terms -- in parallel, more or less how we place up new machines and so forth.

--------------------------------------------------------------------------------

Arvid Necander, Redeye AB, Research Division - Analyst [15]

--------------------------------------------------------------------------------

Okay. Yes, right. And then just a last question. I guess I popped out related to the subject that you talked about before. Related to China, how do you see the reimbursement path? Of course, very hard to speculate, but what's your sense? And if you have any take on that going forward?

--------------------------------------------------------------------------------

The rest is here:
Edited Transcript of XVIVO.ST earnings conference call or presentation 24-Oct-19 12:00pm GMT - Yahoo Finance

Posted in BioEngineering | Comments Off on Edited Transcript of XVIVO.ST earnings conference call or presentation 24-Oct-19 12:00pm GMT – Yahoo Finance

Global Mini Bioreactor Market Size, Share, Growth Rate, Revenue, Applications, Industry Demand & Forecast to 2026 – Galus Australis

Mart Research new study, Global Mini Bioreactor MarketReport cover definite aggressive standpoint including the piece of the overall industry & profiles of the key members working in the worldwide market. The global Mini Bioreactor market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.

Mini Bioreactor Market Segment as follows:

Mini Bioreactor Market by Type (Market Size & Forecast, Major Company of Product Type etc.):

0-50ML

50-100ML

100-250ML

Get a free sample report: https://martresearch.com/contact/request-sample/2/42450

Mini Bioreactor Market by Application (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Biopharmaceutical Companies

CROs

Academic and Research Institutes

Others

Mini Bioreactor Key Companies (Sales Revenue, Price, Gross Margin, Main Products etc.):

Thermo Fisher

Merck KGaA

Danaher (Pall)

GE Healthcare

Sartorius AG (BBI)

ZETA

Eppendorf AG

Pierre Guerin (DCI-Biolafitte)

Praj Hipurity Systems

Bioengineering AG

Infors HT

Applikon Biotechnology

Solaris

Mini Bioreactor By Region

Place the Order of Global Mini Bioreactor Market Research Report: https://martresearch.com/paymentform/2/42450/Single_User

Some Points from Table of Contents:

Chapter 1 Industry Overview

1.1 Mini Bioreactor Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter 2 Mini Bioreactor Market by Type

2.1 By Type

2.1.1 0-50ML

2.1.2 50-100ML

2.1.3 100-250ML

2.2 Market Size by Type

2.3 Market Forecast by Type

Chapter 3 Global Market Demand

3.1 Segment Overview

3.1.1 Biopharmaceutical Companies

3.1.2 CROs

3.1.3 Academic and Research Institutes

3.1.4 Others

3.2 Market Size by Demand

3.3 Market Forecast by Demand

Chapter 4 Major Region Market

4.1 Global Market Overview

4.1.1 Market Size & Growth

4.1.2 Market Forecast

4.2 Major Region

4.2.1 Market Size & Growth

4.2.2 Market Forecast

Chapter 5 Major Companies List

5.1 Thermo Fisher (Company Profile, Sales Data etc.)

5.2 Merck KGaA (Company Profile, Sales Data etc.)

5.3 Danaher (Pall) (Company Profile, Sales Data etc.)

5.4 GE Healthcare (Company Profile, Sales Data etc.)

5.5 Sartorius AG (BBI) (Company Profile, Sales Data etc.)

5.6 ZETA (Company Profile, Sales Data etc.)

5.7 Eppendorf AG (Company Profile, Sales Data etc.)

5.8 Pierre Guerin (DCI-Biolafitte) (Company Profile, Sales Data etc.)

5.9 Praj Hipurity Systems (Company Profile, Sales Data etc.)

5.10 Bioengineering AG (Company Profile, Sales Data etc.)

5.11 Infors HT (Company Profile, Sales Data etc.)

5.12 Applikon Biotechnology (Company Profile, Sales Data etc.)

5.13 Solaris (Company Profile, Sales Data etc.)

Chapter 6 Conclusions

For more Information or Any Query Visit: https://martresearch.com/contact/enquiry/2/42450

List of Tables & Figures

Table Global Mini Bioreactor Market 2016-2019, by Type, in USD Million

Table Global Mini Bioreactor Market 2016-2019, by Type, in Volume

Table Global Mini Bioreactor Market Forecast 2020-2026, by Type, in USD Million

Table Global Mini Bioreactor Market Forecast 2020-2026, by Type, in Volume

Table Global Mini Bioreactor Demand 2016-2019, in USD Million

Table Global Mini Bioreactor Demand 2016-2019, in Volume

Table Global Mini Bioreactor Demand Forecast 2020-2026, in USD Million

Table Global Mini Bioreactor Demand Forecast 2020-2026, in Volume

Table Global Mini Bioreactor Market Size & Growth 2016-2019, in USD Million

Table Global Mini Bioreactor Market Size & Growth 2016-2019, in Volume

Table Global Mini Bioreactor Market Forecast 2020-2026, in USD Million

Table Global Mini Bioreactor Market Forecast 2020-2026, in Volume

Table Global Mini Bioreactor Market 2016-2019, by Region, in USD Million

Table Global Mini Bioreactor Market 2016-2019, by Region, in Volume

Table Global Mini Bioreactor Market Forecast 2020-2026, by Region, in USD Million

KEY QUESTIONS ANSWERED:

About us:

Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.

For More Details Email Us: sales@martresearch.com

View post:
Global Mini Bioreactor Market Size, Share, Growth Rate, Revenue, Applications, Industry Demand & Forecast to 2026 - Galus Australis

Posted in BioEngineering | Comments Off on Global Mini Bioreactor Market Size, Share, Growth Rate, Revenue, Applications, Industry Demand & Forecast to 2026 – Galus Australis

Frontiers in Bioengineering and Biotechnology

The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.

In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically applya new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. Frontiers in Bioengineering and Biotechnology aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.

Frontiers in Bioengineering and Biotechnologyis a member of theCommittee on Publication Ethics.

The rest is here:
Frontiers in Bioengineering and Biotechnology

Posted in BioEngineering | Comments Off on Frontiers in Bioengineering and Biotechnology